Twenty-nine Cases of Enterovirus-D68–associated Acute Flaccid Myelitis in Europe 2016

A Case Series and Epidemiologic Overview

Marjolein Knoester, MD, PhD,* Jelte Helfferich, MD,‡ Randy Poelman, MSc, *
Coretta Van Leer-Buter, MD, PhD,* Oebele F. Brouwer, MD, PhD,† and Hubert G. M. Niesters, PhD,*
on Behalf of the 2016 EV-D68 AFM Working Group

Background: Enterovirus-D68 (EV-D68) is a respiratory virus within the genus Enterovirus and the family of Picornaviridae. Genetically, it is closely related to rhinovirus that replicates in the respiratory tract and causes respiratory disease. Since 2014, EV-D68 has been associated with the neurologic syndrome of acute flaccid myelitis (AFM).

Methods: In October 2016, questionnaires were sent out to a European network including 66 virologists and clinicians, to develop an inventory of EV-D68–associated AFM cases in Europe. Clinical and virologic information of case patients was requested. In addition, epidemiologic information on EV testing was collected for the period between March and October 2016.

Results: Twenty-nine cases of EV-D68–associated AFM were identified, from 12 different European countries. Five originated from France, 5 from Scotland and 3 each from Sweden, Norway and Spain. Twenty-six were children (median age 3.8 years), 3 were adults. EV-D68 was detected in respiratory materials (n = 27), feces (n = 8) and/or cerebrospinal fluid (n = 2). Common clinical features were asymmetric flaccid limb weakness, cranial nerve deficits and bulbar symptoms. On magnetic resonance imaging, typical findings were hyperintensity of the central cord and/or brainstem; low motor amplitudes with normal conduction velocities were seen on electromyography. Full clinical recovery was rare (n = 3), and 2 patients died. The epidemiologic data from 16 European laboratories showed that of all EV-D68–positive samples, 99% was detected in a respiratory specimen.

Conclusions: For 2016, 29 EV-D68–related AFM cases were identified in the United States, with the most common virus detected in upper respiratory tract specimens being EV-D68. AFM is a polio-like neurologic condition, characterized by an acute onset of asymmetric multifocal limb weakness with spinal cord lesions evident on magnetic resonance imaging (MRI). An epidemiologic link was made between the AFM upsurge and the concurrent EV-D68 outbreak in the United States. During the same period, 4 AFM patients with respiratory EV-D68 infections were reported in Europe.

In the winter of 2015/2016, 2 AFM cases with concurrent EV-D68 infection were identified in Wales, and in July 2016, a severe case of EV-D68–related AFM in a 4-year-old boy was identified in the Netherlands. Subsequently, through an e-mail alert to the previously established ESCV-ECDC EV-D68 study group network, more cases of EV-D68–related AFM were rapidly identified. An intense collaboration between virologists and clinicians (ie, pediatric neurologists and infection disease specialists) from across Europe was established. In this article, we present the clinical and virologic data of the 29 cases that were identified through this network, to illustrate the clinical picture and to improve future patient identification.

The 2014 ESCV-ECDC collaborative work showed that only limited data were available on the epidemiology of respiratory EV infections. This was especially, but not exclusively, the case for Eastern and Southern European countries, among others because of a lack of diagnostic testing and typing of EVs in respiratory samples. In line with our study in 2014, we collected epidemiologic data for Europe in 2016. We present data on EV and EV-D68
testing and positivity rates, to emphasize the impact of adequate diagnostics, and on notification regulations of AFM in the various European countries.

**MATERIALS AND METHODS**

Members of the 2014 ESCV-ECDC EV-D68 study group, mostly virologists, were contacted by the coordinating center (University Medical Center, Groningen, The Netherlands) through an e-mail alert. Additionally, EV reference laboratories in Eastern Europe were informed of the initiative, as they were underrepresented in the study group. Finally, through this network and in reply to scientific presentations or publications on the subject, we contacted clinicians who diagnosed or treated a patient with EV-D68–related AFM. The collaborating centers and clinicians (from this point on referred to as the the 2016 EV-D68 AFM Working Group, with 66 members (Supplemental Digital Content 1, http://links.lww.com/INF/D269) were sent a questionnaire by which they were asked to report the number of EV-D68–related AFM cases diagnosed in 2016. For each case, information was inquired regarding age, gender, prodromal phase, neurologic abnormalities (mental status, signs of nuchal rigidity, cranial nerve dysfunction, limb weakness, tendon reflexes and sensory disturbances), virologic diagnostics, neurologic investigations [cerebrospinal fluid (CSF) analysis, MRI, electromyography (EMG)] and clinical follow-up. Additionally, information on diagnostic EV testing was collected via the questionnaire. For the period between March and October 2016, we requested the number of EV tests performed on all clinical specimens (respiratory, CSF, feces and blood), the number of EV-positive tests and the number of EV-D68–positive tests. Twenty-one laboratories responded, including both diagnostic and reference laboratories. The national reference center of Bulgaria reported that EV detection was performed in their institution, and reference laboratories. The national reference center of Bulgaria reported that EV detection was performed in their institution, and reference laboratories.

We received the clinical data from 29 EV-D68–related AFM cases, from 12 different countries. Table 1 shows the clinical data of these cases (more extensive descriptions can be found in the Table, Supplemental Digital Content 2, http://links.lww.com/INF/D270). The distribution of cases over Europe is shown in the (Figure, Supplemental Digital Content 3, http://links.lww.com/INF/D271). Twenty-six children were affected, with a median age of 3.8 years (range 1.6–9.0) and 3 adults were included in this series. Gender was equally distributed. EV-D68 was detected in a respiratory sample of 27 patients, in the feces of 8 patients and in the CSF of 2 patients. Only 1 child was coinfected with another neurotropic virus, EV-A71.

Medical history was nonsignificant, except for an adult patient who received an allogeneic hematopoietic stem cell transplantation for Non-Hodgkin B-cell lymphoma 2 years earlier. A prodomal phase with fever (n = 24) and/or respiratory symptoms (n = 26) preceded weakness by a median period of 2 days. Weakness was flaccid and usually asymmetric, with decreased or absent reflexes. Upper limbs were more frequently and often more severely affected than lower limbs. Cranial nerve deficits were common (n = 17). Nineteen patients needed ventilatory support. Information on duration of ventilator dependency was scarce, but at least 7 children needed tracheostomy for long-term ventilator support.

Case Definition EV-D68–related AFM

AFM is a specific form of AFS. Its definition was stated in 2015 and adapted since by the Centers for Disease Control and Prevention. The 3 key components of the EV-D68–related AFM case definition are: (1) Acute onset of focal limb weakness, (2) MRI showing a spinal cord lesion largely restricted to the grey matter and spanning 1 or more spinal segments and (3) Detection of EV-D68 in a respiratory, fecal, blood or CSF specimen using a validated polymerase chain reaction (PCR) assay for EV-D68, or a validated PCR assay for EVs in general and subsequent sequencing and typing. If MRI is not performed, or findings are normal, and the CSF shows pleocytosis, the patient is considered a “probable” case.

Typing and Phylogenetic Mapping

To compare the viral sequences, the collaborating centers were asked to share the sequencing files of their EV-D68 cases (both of respiratory and AFM cases). Alternatively, samples could be sent to one of the participating laboratories for sequencing. Typing was performed using the standard method described by Nix et al, which consists of partial sequencing of the viral protein 1. Phylogenetic analysis was performed using BioNumerics Software version 6.6 (Applied Maths, Sint-Martens-Latem, Belgium).

**Ethics Approval**

The research ethics committee of the coordinating center confirmed exemption from the Medical Research Involving Human Subjects Act (Decree M17.207412). Local ethics approval and informed consent from participating patients or their parents were obtained according to individual institutional requirements.

**RESULTS**

**EV-D68–related AFM Cases**

We received the clinical data from 29 EV-D68–related AFM cases, from 12 different countries. Table 1 shows the clinical data of these cases (more extensive descriptions can be found in the Table, Supplemental Digital Content 2, http://links.lww.com/INF/D270). The distribution of cases over Europe is shown in the (Figure, Supplemental Digital Content 3, http://links.lww.com/INF/D271). Twenty-six children were affected, with a median age of 3.8 years (range 1.6–9.0) and 3 adults were included in this series. Gender was equally distributed. EV-D68 was detected in a respiratory sample of 27 patients, in the feces of 8 patients and in the CSF of 2 patients. Only 1 child was coinfected with another neurotropic virus, EV-A71.

Medical history was nonsignificant, except for an adult patient who received an allogeneic hematopoietic stem cell transplantation for Non-Hodgkin B-cell lymphoma 2 years earlier. A prodomal phase with fever (n = 24) and/or respiratory symptoms (n = 26) preceded weakness by a median period of 2 days. Weakness was flaccid and usually asymmetric, with decreased or absent reflexes. Upper limbs were more frequently and often more severely affected than lower limbs. Cranial nerve deficits were common (n = 17). Nineteen patients needed ventilatory support. Information on duration of ventilator dependency was scarce, but at least 7 children needed tracheostomy for long-term ventilator support.

**Epidemiology and Diagnostics**

From March to October 2016, 21,875 EV tests were reported by 16 European laboratories, as shown in the Table (Supplemental Digital Content 4, http://links.lww.com/INF/D272). This table does not contain the data from EV-D68 AFM cases that were reported by clinicians without epidemiologic data from the diagnostic laboratory, so it has only a partial overlap with Table 1. Of the 21,875 EV tests reported on all clinical specimens, 2111 were EV-positive (10%; excluding those EV-positive samples for which no
**TABLE 1. Clinical Description of 29 Enterovirus-D68–related Acute Flaccid Myelitis Cases, Europe 2016**

<table>
<thead>
<tr>
<th>Data Available for n=</th>
<th>No. (Percentage or Range)</th>
</tr>
</thead>
</table>

**Demographics**
- Median age (yr) 29 4 (1.6–55)
- Male gender 29 15 (52%)

**Prodromal symptoms**
- Fever 26 24 (92%)
- Respiratory symptoms 29 26 (90%)
- Gastrointestinal symptoms 29 7 (24%)
- Median days of fever until onset of weakness 22 2 (0–8)

**Neurologic symptoms**
- Cranial nerves affected 28 17 (60%)
  - Facial nerve palsy 8 (29%)
  - Bulbar symptoms 9 (32%)
  - Eye movement disorders 5 (18%)
- Ventilatory support needed 29 19 (66%)
- Limb weakness 29 29 (100%)
  - 1 limb 3 (10%)
  - 2 limbs 8 (28%)
  - 3 limbs 0 (0%)
  - 4 limbs 16 (55%)
  - Limbs not specified 2 (7%)
- Hyporeflexia/areflexia 22 20 (87%)
- Other symptoms 29
  - Autonomic dysfunction, n = 3
  - Acute respiratory distress syndrome, n = 1
  - Generalized convulsions, n = 1
  - Limb ataxia, n = 1
  - Limb pain, n = 4
  - Neurogenic bladder dysfunction, n = 1
  - Paresthesia, n = 2
  - Pneumonia, n = 4
  - Transient myocardial dysfunction, n = 1

**CSF analysis**
- Pleocytosis (CSF cell count >5 leukocytes/µL) 22 20 (91%)
- Median CSF cell count (leukocytes/µL) 20 79 (3–416)
- Median CSF protein level (g/L) 17 0.38 (0.21–1.6)

**MRI abnormalities**
- MRI: Hyperintensity central cord 25 23 (92%)
  - Location (if specified) 20
    - Cervical, n = 10
    - Cervical/thoracic, n = 6
    - Thoracic/lumbar, n = 1
    - Entire spinal cord, n = 3
- MRI brain: Hyperintensity dorsal pons/medulla 25 17 (68%)
  - Other MRI abnormalities 6
    - Enhancing roots, n = 4
    - Meningeal enhancement, n = 1
    - Hyperintensity dentate nuclei, dorsal medulla, n = 1

**Electromyography**
- Low motor amplitudes 11 10 (91%)
- Reduced conduction velocities 1 (9%)
- Spontaneous muscle fiber activity 5 (45%)

**Treatment**
- Intravenous immunoglobulin 24 20 (83%)
- Intravenous steroids 17 (71%)
- Plasmapheresis 5 (21%)
- Other
  - Fluoxetine, n = 1; rituximab, n = 1

**Follow-up**
- Full recovery 28 3 (11%)
- Partial recovery 21 (75%)
- No recovery 2 (7%)
- Death 2 (7%)
- Median follow-up time (mo) 24 4 (0.5–12)

**Virology**
- EV-D68 positive in:
  - Any sample 29 29 (100%)
  - CSF 25 2 (8%)
  - Respiratory sample 28 27 (96%)
  - Fecal sample 22 8 (36%)

Two patients were diagnosed in December 2015. Sixteen cases were previously reported in separate publications.10,11,13–18
denominator was given). Of the total number of 2381 EV-positive samples, 416 were EV-D68 (17%). Taking a closer look at respiratory samples, 10,226 EV tests were performed, with 987 (10%) EV-positive samples. Of the total amount of 1067 EV-positive samples in respiratory specimens, 414 were EV-D68 positive (39%). Only 1 of 558 EV-positive CSF samples (0.18%) and 1 of 711 EV-positive feces samples (0.14%) was positive for EV-D68 (data not shown in the table).

Sequence data of the viral protein 1 region were available for 6 of 29 AFM patients, and together with many other EV-D68 strains of 2014 and 2016, these were used for sequence analysis. The Figure (Supplemental Digital Content 5, http://links.lww.com/INF/D273) shows the dominance of the B3 clade in 2016, irrespective of respiratory or neurologic symptoms.

Notification Regulations
The following information was obtained regarding notification regulations: AFP/AFM is a reportable disease in all European countries within the scope of polio eradication. Only in Norway, also non-polio AFP/AFM cases are notifiable and the requirement of a respiratory sample for testing was added after the EV-D68 outbreak in 2014. In Germany and France, non-polio AFP/AFM is voluntarily reported. In Norway, Sweden, Ireland, Italy, France and Slovenia, (entero-) (viral) meningitis/encephalitis is reportable. In Denmark, EV meningitis and paralysis are reportable and recently the required specimens for testing were expanded with a respiratory sample. For the remaining countries, no clear regulations exist for non-polio AFP/AFM cases.

DISCUSSION
The association between EV-D68 and AFM has become clear since 2014, although causality was not yet proven. The recent publication of a mouse model, in which mice that had been inoculated with EV-D68 developed symptoms of myelitis, added important evidence supporting causality. Furthermore, using the Bradford-Hill criteria, 2 groups evaluated both the epidemiologic and biologic evidence linking EV-D68 to AFM. Several case reports and small case series have been published from the United States, Canada, South America, Australia, Asia and Europe, describing patients with EV-D68–related AFM.19 In this article, we presented the first comprehensive EV-D68 AFM case series and an epidemiologic overview for Europe in 2016.

Clinical Manifestations and Treatment
In children, the median age of 3.8 years at onset of AFM was in line with the median age in a Japanese EV-D68–related AFM upsurge in 2015 (4.4 years), but somewhat lower than the median age of those affected in 2014 in the United States (7.1 years). If this is a true difference, it would be interesting to investigate if lower serologic protection rates in the 4-year-olds in 2016 could have caused this shift. We included the 3 adult cases in our series to point out that EV-D68–related AFM is not restricted to childhood age.

The clinical presentation of the affected patients in Europe 2016 resembled that of patients from other parts of the world regarding prodromal symptoms and neurologic manifestations, with asymmetric flaccid limb weakness, sometimes accompanied...
by pain, cranial nerve deficits and bulbar symptoms. It may be difficult to distinguish AFM clinically from other neurologic diseases, such as Guillain–Barre syndrome, acute transverse myelitis, Miller Fisher syndrome or acute disseminated encephalomyelitis. Additionally, mild cases can be easily missed. The case definition provides descriptions of specific MRI lesions along the spinal cord. Additionally, in the literature, lesions in the grey matter of the anterior horn and in the brainstem are described, as well as contrast enhancement of nerve roots. When MRI is not performed or these specific MRI lesions are not (yet) visible, patients may meet the criteria of a probable case when they show a mild CSF pleocytosis, as did 1 of our patients. Two patients strictly did not fulfill the criteria of the case definition, as MRI results and CSF analyses were lacking. They were nevertheless included in this study, based on the clinical picture of AFM with respiratory insufficiency and/or bulbar symptoms, and the detection of EV-D68 in respiratory samples.

If feasible in the young child, EMG findings can be of great value in supporting the diagnosis of AFM. Thus far, children with EV-D68–associated AFM generally showed low amplitude compound muscle action potentials, most often with normal conduction velocity, without signs of sensory nerve conduction abnormalities. In a later stage of disease, spontaneous muscle fiber activity can be found in the affected muscles.

Although an attempt was made to capture the features of EV-D68–related AFM in a case definition, it should be emphasized that EV-D68 is not the only virus that can cause AFM. For example, West-Nile virus and other EVs, such as EV-A71, should be considered as causative agents. Neither is AFM the only neurologic disorder that is associated with EV-D68 infection; EV-D68 has been found in patients with rhombencephalitis and, in this cases series, 1 child from France was submitted with a Guillain–Barre syndrome and a concurrent EV-D68 infection (data not shown).

Various treatment regimens were prescribed in this case series. It is unfortunately not possible to deduce any positive or negative effects from these data. Similarly, in other series, no therapeutic intervention seemed to have significantly improved outcome. However, with a mouse model, Hixon et al. showed that EV-D68 immune-sera protected mice from development of paralysis and death when administered before viral challenge. Furthermore, recent data using this mouse model showed a favorable effect of intravenous immunoglobulin administered after infection as well; high-dose corticosteroids, however, had a negative effect on motor function and mortality. Because of these findings, treatment protocols with corticosteroids as a first-line treatment may be subject to discussion.

In the literature, full neurologic rehabilitation has occurred only in a minority of patients after a 12- to 18-month period of follow-up, although MRI lesions may disappear. The 2016 EV-D68 AFM Working Group aims at a standardized follow-up of the European patients beyond 12 months after the onset of illness, to get more insight in the natural course of the disease and to further improve education of patients and parents on the prognosis of EV-D68–related AFM.

In this series, the 2 patients who showed EV-D68 in the CSF did not survive. This may imply more severe disease, but larger studies are needed to evaluate this.

**Epidemiology and Diagnostics**

Our data showed a wide range of both EV positivity rates and EV-D68 positivity rates between the laboratories. This is likely explained by differences in non-polio EV-surveillance strategies and testing and typing algorithms in Europe, as mapped out by Harvala et al. A way to overcome these differences would be the intensification of non-polio EV-surveillance, such as initiated in Denmark and by the European non-polio EV network.

Standard EV diagnostics, as well as poliovirus surveillance, generally relies on testing in feces, as poliovirus and the majority of other EV serotypes can indeed be detected in fecal samples. However, our epidemiologic data show that 99% of EV-D68–positive samples were respiratory specimens. This underlines that EV-D68 has a predominant respiratory tropism and respiratory specimens are required for identification of the virus. The near absence of EV-D68 in fecal samples is in line with a previous study. However, in our case series, EV-D68 was more frequently detected in feces and CSF than was expected based on our epidemiologic data. This difference likely reflects the widespread occurrence of EV-D68 respiratory disease, with the virus being present in respiratory specimens, and the rarity of EV-D68–related AFM, with the virus potentially present in multiple compartments, plus a more thorough microbiologic investigation in AFM patients because of disease severity.

Recently, the World Health Organization and the Pan American Health Organization have released an epidemiologic alert to include testing for EV-D68 on respiratory samples in cases of AFS/AFM, both for case management and for surveillance purposes. It is important to note that not all respiratory PCR panels include EV as a target. Second, not all molecular tests that target EVs are able to detect EV-D68 or distinguish EV-D68 from rhinoviruses. Communication between clinicians and virologists is therefore essential to optimize diagnostics.

Sequence analysis showed that most of the EV-D68 strains in 2014 clustered with clades A1, A2, B1 and B2. In 2016, however, nearly all strains belonged to subclade B3 in Europe as well as in the United States. The clinical importance of this shift is yet unclear.

This study reveals that crucial information is often not (timely) available, among others by a lack of non-polio AFS/AFM notification regulations, and therefore the overview is by no means complete. By activating the 2016 EV-D68 AFM Working Group network, we were able to identify 29 EV-D68–related AFM cases in Europe in 2016, but these probably represent only the tip of the iceberg. All cases were reported by countries that had also joined in the 2014 initiative. Clearly, these countries were already interested in EV-associated diseases and were therefore more prompted to identify cases when confronted with paralyzed patients. Additional AFM cases that may have been due to EV-D68 but did not have etiology confirmed because of late or absent sampling and testing, likely have been missed.

As EV-D68 has shown a cyclic pattern since 2010, it is conceivable that the virus might reappear in the very near future. As no major changes have occurred in making AFM reportable in Europe, a new outbreak may go largely undetected by the health authorities. In the short term, we might benefit most from an e-mail alert system, by which clinicians and laboratories inform each other on the start of the EV season, the upsurge of rare types and on specific EV-associated syndromes, as AFM.

**REFERENCES**
